OVERVIEW

The Right End-to-End Partner for Rheumatoid Arthritis Clinical Trials

Rheumatology is one of the fastest changing therapeutic areas. The availability of biosimilars approved for use in rheumatoid arthritis (RA) has made biologics more accessible, but there remains a significant opportunity for novel treatments and modes of action.

PPD provides end-to-end clinical development expertise in RA and a global team of experienced professionals to deliver your study on time and on budget. Our experts understand how to best place and run studies in a crowded space, operationalizing RA trials to enable quick and dynamic study execution. Our approach will ensure your compound gets to market with a focus on delivering speed and the highest quality data, minimizing known impacts on placebo response rates.

28 RA studies enrolling over **4,700 patients globally**

More than **1,000 RA sites** in over **30 countries** had visits from PPD clinical staff in the **last 12 months**

Proven Speed to Market

PPD's team of RA experts has successfully delivered their last five studies ahead of schedule through detailed planning and management.

- In a recent Phase III study, **80% of sites were activated** within the first week after the investigator meeting
- A recently completed Phase II study **reached last patient in 4 months ahead of schedule**

Optimize Site Selection with PPD's Experienced RA Team

PPD's access to key opinion and thought leaders in rheumatology includes internal and external reach. Our experienced team of rheumatologists will provide therapeutic oversight and recommendations related to all aspects of the clinical program.

- PPD has more than 340 RA-experienced staff across all four main regions
- PPD has established relationships with more than 3,000 rheumatology sites globally, over 830 of which are known high performers in RA
- PPD has high performing sites in Bulgaria, Italy, Ukraine, Poland, Serbia, and India, allowing for faster start-up and proven enrollment

Through our relationships with principal investigators, PPD has access to capability and performance metrics enabling identification of the best sites. This data gives PPD a significant advantage in developing proven, strategic study planning and execution.

Data Quality Assurance

PPD has a reputation built on data quality, and we understand the importance of maintaining the highest level of accurate, complete, and clean data throughout each clinical trial.

- Advanced data cleaning process customized to the needs of rheumatology studies:
  - A focus on critical endpoint data, particularly on swollen and tender joint counts
  - Training of site staff on the conduct of these assessments
- Proven results in handling regulatory audits
- Leading set of technologies to guarantee data quality, including advancements in trial digitization to minimize data impact due to the global pandemic

PPD's experts in market access can support you in differentiating your RA compound in a crowded market, including planning for labeling claims throughout the development life cycle

PPD provides end-to-end solutions to cover every aspect of RA clinical research. From early development, to trial enrollment and data quality, all the way through market access, **PPD designs innovative, customized solutions** across the full drug development life cycle to deliver life-changing therapies with speed and efficiency.

North America +1 877 643 8773 | Europe + 1 919 456 5600